Medicure's MC-1 seizure drug for PNPO deficiency receives FDA's Fast Track Designation.
Medicure Inc. has received Fast Track Designation from the US FDA for MC-1, a drug targeting seizures in PNPO deficiency patients. This designation aims to expedite development and review of drugs addressing serious conditions with unmet medical needs. MC-1 is in a Phase 3 clinical trial, with the potential for Medicure to receive a priority review voucher from the FDA upon approval.
April 23, 2024
5 Articles